Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia

Valencia, Ana; Cervera, José; Such, Esperanza; Barragán, Eva; Bolufer, Pascual; Fuster, Óscar; Collado, Rosa; Martı́nez, Jesús; Sanz, Miguel Á.

doi:10.1155/2009/187125

Cited by 17 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic impact of the variant translocations was reported in many studies. However, some authors have stated that the involvement of additional oncogenes could be associated with poorer prognosis [ 10 , 13 , 14 ], while the majority of related studies have confirmed no difference in the prognosis between standard and variant translocations [ 2 , 5 , 9 , 15 , 16 , 17 ]. The ELN recommendations do not provide any specific advice for patients with variant translocations [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia

Eyupoglu¹,

Bozkurt²,

Haznedaroğlu³

et al. 2016

Tjh

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22) with the formation of Philadelphia (Ph) chromosome. Sometimes, the Ph translocation is generated by variant rearrangements. The prognostic impact of the variant translocations is still controversial. Among the 180 patients with Ph-positive CML who were treated in Hacettepe University Faculty of Medicine Division of Hematology, variant translocations were detected, and retrospectively clinical and prognostic features were described. Also we performed a comprehensive literature review on the prognosis of such variant cases before and after tyrosine kinase inhibitor era. Five patients (2.7%) had variant Ph chromosomes, involved in the rearrangements were chromosomes 2 (2 cases), 11, 14 and 15. Patients were treated with imatinib or dasatinib. All patients reached a stable major molecular response suggesting a prognosis not worse than standard translocation individuals. Our present data were compatible with the data of previous studies indicating no difference in the prognosis between standard and variant translocations in tyrosine kinase inhibitors era of CML.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia

Eyupoglu¹,

Bozkurt²,

Haznedaroğlu³

et al. 2016

Tjh

View full text Add to dashboard Cite

show abstract

“…Magnetic resonance imaging has been used in examining fetuses suspected of infection but its use is controversial. 32,33 Normal brain imaging does not necessarily predict normal neurodevelopmental outcome, particularly since hearing loss is frequently progressive in congenital CMV. 34 At this time, the data regarding the addition of magnetic resonance imaging to ultrasound evaluation are insufficient to recommend routine use in evaluation for congenital CMV infection.…”

Section: What Is the Role Of Imaging In Assessing Fetal Infection?mentioning

confidence: 99%

Diagnosis and antenatal management of congenital cytomegalovirus infection

Hughes¹,

Gyamfi-Bannerman²

2016

American Journal of Obstetrics and Gynecology

142

104

View full text Add to dashboard Cite

Congenital cytomegalovirus (CMV) is the most common viral infection, affecting nearly 40,000 infants each year in the United States. Of seronegative women, 1-4% will acquire a primary infection during pregnancy, and the majority of these women will be asymptomatic. Prior maternal exposure to CMV does not preclude neonatal infection. The purpose of this document is to review diagnosis of primary maternal CMV infection, diagnosis of fetal CMV infection, and whether antenatal therapy is warranted. We recommend the following: (1) that women with a diagnosis of primary CMV infection in pregnancy be advised that the risk of congenital infection is 30-50%, on average, and that the severity of infection varies widely (Best Practice); (2) for women suspected of having primary CMV infection in pregnancy, we recommend that diagnosis should be either by IgG seroconversion or with positive CMV IgM, positive IgG, and low IgG avidity (grade 1B); (3) amniocentesis is the best option as a prenatal diagnostic tool to detect fetal congenital CMV infection, performed >21 weeks of gestation and >6 weeks from maternal infection (grade 1C); (4) we do not recommend routine screening of all pregnant women for evidence of primary CMV infection at this time (grade 1B); and (5) we do not recommend antenatal treatment with ganciclovir or valacyclovir; and we recommend that any antenatal therapy, either with antivirals or CMV hyperimmune globulin, should only be offered as part of a research protocol (Best Practice).

show abstract

“…Additionally, several reports have found that Philadelphia chromosome variant patients tend to have a similar prognosis to those with the classic Philadelphia translocation when treated with imatinib therapy (10).…”

Section: Discussionmentioning

confidence: 99%

A novel three‑way Philadelphia Variant t(9;22;17)(q34;q11.2;q12) in chronic myeloid leukemia: A case report

Allen-Proctor

Ruckdeschel

2017

mol clin onc

View full text Add to dashboard Cite

Abstract. Chronic myeloid leukemia (CML) is a hematologic malignancy associated with increased circulating myeloid cells and platelets in the peripheral blood, with accompanying bone marrow hyperplasia. The Philadelphia chromosome, t(9;22)(q34;q11), is present in 95% of CML patients, resulting in constitutive tyrosine kinase activity; however, ~5% of CML patients possess a Philadelphia variant. A novel three-way Philadelphia translocation variant, t(9;22;17)(q34;q11.2;q11.2), was identified in a 54-year old man who presented with leukocytosis, anemia and thrombocytosis that was diagnosed with chronic myeloid leukemia, chronic phase. Cytogenetic analysis by G-banding revealed the presence of a three-way translocation involving the long arms of chromosomes 9, 22 and 17. Fluorescence is situ hybridization utilizing a dual-color fusion probe confirmed the presence of the Bcr-Abl fusion gene.

show abstract

Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia

Cited by 17 publications

References 8 publications

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia

Diagnosis and antenatal management of congenital cytomegalovirus infection

A novel three‑way Philadelphia Variant t(9;22;17)(q34;q11.2;q12) in chronic myeloid leukemia: A case report

Contact Info

Product

Resources

About